

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Simcere Pharmaceutical Group Limited

先聲藥業集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 2096)

VOLUNTARY ANNOUNCEMENT

ENTERING INTO AN EXCLUSIVE PROMOTION SERVICE AGREEMENT WITH PRIMEGENX THERAPEUTICS IN RELATION TO PUMECITINIB GEL

This announcement is made by Simcere Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform shareholders and potential investors of the Company regarding the latest business development of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that, on June 1, 2026, the Group entered into an exclusive promotion service agreement (the “**Agreement**”) with PrimeGenX Therapeutics Co., Ltd. (北京普祺醫藥科技股份有限公司) (“**PrimeGenX Therapeutics**”) in relation to Pumecitinib Gel. Pursuant to the Agreement, the Group will obtain the exclusive promotion rights for Pumecitinib Gel for all dermatology indications in Mainland China, Hong Kong, and Macau. The New Drug Application (NDA) of Pumecitinib Gel for the indication of atopic dermatitis (“**AD**”) in adults and adolescents has been accepted for review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration. This collaboration will further strengthen the Group’s product portfolio in the field of autoimmune diseases.

ABOUT PUMECITINIB GEL

Pumecitinib Gel is the world’s first JAK inhibitor gel indicated for the treatment of AD. Clinical trial results for mild-to-moderate AD in adults and adolescents aged 12 and above demonstrated that, compared with the placebo, Pumecitinib Gel significantly improved patients’ skin lesions and related clinical symptoms, while presenting a favorable safety and

tolerability profile alongside low plasma concentration. Furthermore, Pumecitinib Gel is non-greasy, easy to apply, and spreads evenly over the skin with a gentle and soothing feel, which addresses the greasy texture common in certain traditional topical formulations and helps improve patient compliance. Pumecitinib Gel is continuously expanding its indication layout within the dermatology field, such as AD in children aged 2 to 11, prurigo nodularis, and non-segmental vitiligo.

ABOUT PRIMEGENX THERAPEUTICS

PrimeGenX Therapeutics is a biotechnology company focused on the treatment of inflammatory diseases through local delivery of targeted therapies. Deeply engaged in the field of chronic inflammatory diseases, it aims to provide comprehensive solutions that combine efficacy, safety, and long-term patient satisfaction. Leveraging its proven, integrated drug discovery and development platform, PrimeGenX Therapeutics has developed its core products, including Pumecitinib Gel for atopic dermatitis and Pumecitinib Nasal Spray for allergic rhinitis as well as other Class 1 innovative drugs with global leading potential, such as PG-033 Tablets for pruritus, PG-018 Tablets for autoimmune nephropathy, and PG-040 Eye Drops for glaucoma.

ABOUT THE GROUP

The Company is an innovation and R&D-driven pharmaceutical company and the Group has established a “State Key Laboratory of Neurology and Oncology Drug Development”. The Group focuses on the therapeutic areas of neuroscience, anti-oncology, autoimmune and anti-infection, with forward-looking layout of disease areas that may have significant clinical needs in the future, aiming to achieve the mission of “for patients, for life”. Driven by its in-house R&D efforts and synergistic innovation, the Company has established strategic cooperation partnerships with many innovative companies and research institutes.

By order of the Board
Simcere Pharmaceutical Group Limited
Mr. Ren Jinsheng
Chairman and Executive Director

Hong Kong, June 1, 2026

As at the date of this announcement, the Board comprises Mr. REN Jinsheng as the Chairman and executive Director; Mr. TANG Renhong, Mr. WAN Yushan and Ms. WANG Xi as the executive Directors; Mr. SONG Ruilin, Mr. WANG Jianguo, Mr. WANG Xinhua and Mr. SUNG Ka Woon as the independent non-executive Directors.